Roche’s live audio webcast and conference call from ESMO IO 2017
| Agenda: | |
|---|---|
| IMpower150: Phase 3 results of carboplatin + paclitaxel +/- Avastin, with or without Tecentriq in 1L non-squamous metastatic NSCLC | Alan Sandler, M.D., Global Development Team Leader Tecentriq Lung |
| Tecentriq program overview: Focusing on novel combination approaches | Cathi Ahearn, Global Product Strategy Tecentriq |
Please register to access the replay* *Privacy notice